GlassScriptPhysician profile
Jennifer Tyson
NPI 1134964307
$586.12
in general payments reported to CMS, 2019-2025
13 companies · $344 in 2025
The $344 reported for 2025 was more than what a typical Gerontology (Nurse Practitioner) provider received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $242 · 2025: $344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $586.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Silk Road Medical, INC. | $158.03 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Novo Nordisk INC | $109.75 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $58.76 | 2025 | Freestyle Libre 3 |
| Pfizer INC. | $58.64 | 2025 | |
| Corcept Therapeutics | $34.39 | 2025 | Korlym |
| Merck Sharp & Dohme LLC | $30.56 | 2025 | Capvaxive |
| Neurocrine Biosciences, INC. | $28.00 | 2025 | |
| Abbvie INC. | $24.65 | 2025 | |
| Smith+Nephew, INC. | $19.29 | 2024 | Oasis, Grafix |
| Viatris Specialty LLC | $18.53 | 2025 | Yupelri |
| Amgen INC. | $16.63 | 2024 | Prolia, Evenity |
| Sumitomo Pharma America, INC. | $14.71 | 2025 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $14.18 | 2025 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Tyson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.